Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15595187 | 0.89 | OGA (0.46) | HDAC11SIGMAR1MAPT | |
| SCHEMBL18922700 | 0.89 | OGA (0.46) | HDAC11SIGMAR1MAPT | |
| SCHEMBL20494615 | 0.88 | SIGMAR1 (0.40) | SIGMAR1MAPTDRD4OPRK1L3MBTL1 | |
| SCHEMBL3398912 | 0.85 | CTSL (0.54) | HDAC11 | |
| SCHEMBL19875824 | 0.85 | SIGMAR1 (0.52) | SIGMAR1L3MBTL1 | |
| SCHEMBL21166309 | 0.83 | KMT2A (0.59) | HDAC11SIGMAR1MAPTL3MBTL1 | |
| SCHEMBL16978164 | 0.81 | BRD4 (0.47) | MAPT | |
| SCHEMBL23326734 | 0.78 | HDAC11 (0.45) | HDAC11SIGMAR1MAPT | |
| SCHEMBL20495207 | 0.78 | HDAC11 (0.45) | HDAC11SIGMAR1MAPT | |
| SCHEMBL20495223 | 0.78 | HDAC11 (0.45) | HDAC11SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2018165611-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | HDAC11 780/4885SIGMAR1 1660/4885MAPT 2009/4885 |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | HDAC11 1650/4885SIGMAR1 453/4885MAPT 3634/4885 |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | ABCB11, ABCB1, ABCG2 | HDAC11 1650/4885SIGMAR1 453/4885MAPT 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.